Profile data is unavailable for this security.
About the company
Perrigo Company plc is an Ireland-based provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. The Company's segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises its consumer self-care business (OTC, infant formula, and oral care categories, and contract manufacturing) in the United States and Canada, including the HRA Pharma self-care business (Women's Health and Skin-Care categories) in the United States and Canada. The CSCI segment comprises its consumer self-care business in Europe and Australia, which are primarily branded, its store brand business in the United Kingdom and parts of Europe and Asia and includes the HRA Pharma self-care business (Women's Health, Skin-Care and Rare-Disease categories) in Europe. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, Nutrition and others.
- Revenue in USD (TTM)4.56bn
- Net income in USD700.00k
- Incorporated2013
- Employees9.14k
- LocationPerrigo Company PLCThe Sharp BuildingHogan Place, Dublin 2DUBLIN D02 TY74IrelandIRL
- Phone+353 17094000
- Websitehttps://www.perrigo.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Catalyst Pharmaceuticals Inc | 411.35m | 65.12m | 1.87bn | 167.00 | 29.34 | 3.32 | 18.51 | 4.54 | 0.5384 | 0.5384 | 3.60 | 4.76 | 0.7806 | 3.60 | 8.76 | 2,463,156.00 | 12.36 | 25.42 | 14.19 | 29.81 | 86.74 | 85.63 | 15.83 | 30.87 | 4.83 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
Amneal Pharmaceuticals Inc | 2.50bn | -168.69m | 2.02bn | 7.70k | -- | -- | 18.96 | 0.809 | -0.5642 | -0.5642 | 11.52 | -0.2065 | 0.7046 | 2.94 | 4.11 | 324,059.50 | -3.40 | -4.80 | -4.27 | -5.93 | 35.28 | 34.76 | -4.82 | -9.00 | 0.97 | 1.27 | 1.01 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
Vericel Corp | 207.78m | 451.00k | 2.19bn | 314.00 | 4,714.44 | 9.34 | 405.64 | 10.54 | 0.0096 | 0.0096 | 4.35 | 4.82 | 0.6684 | 4.38 | 4.71 | 661,719.80 | 0.1451 | -3.07 | 0.1621 | -3.50 | 69.50 | 67.87 | 0.2171 | -4.49 | 4.83 | -- | 0.0007 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
ADMA Biologics Inc | 283.18m | -3.64m | 2.64bn | 624.00 | -- | 17.19 | 554.14 | 9.33 | -0.0204 | -0.0204 | 1.23 | 0.6632 | 0.8188 | 0.9923 | 7.44 | 453,808.40 | -1.05 | -24.80 | -1.21 | -28.00 | 40.13 | 17.40 | -1.29 | -51.31 | 1.86 | 2.19 | 0.4598 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
Twist Bioscience Corp | 277.49m | -192.14m | 2.76bn | 919.00 | -- | 4.91 | -- | 9.93 | -3.35 | -3.35 | 4.83 | 9.63 | 0.3565 | 4.87 | 7.04 | 301,943.40 | -24.68 | -30.50 | -27.12 | -33.84 | 38.29 | 36.02 | -69.24 | -113.33 | 5.06 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
Corcept Therapeutics Incorporated | 523.53m | 118.02m | 3.29bn | 352.00 | 29.52 | 5.99 | 27.61 | 6.28 | 1.07 | 1.07 | 4.74 | 5.27 | 0.822 | 1.12 | 11.13 | 1,487,298.00 | 18.53 | 21.17 | 21.50 | 23.85 | 98.54 | 98.52 | 22.54 | 27.23 | 5.10 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
Prestige Consumer Healthcare Inc | 1.13bn | 209.34m | 3.41bn | 570.00 | 16.37 | 2.06 | 14.20 | 3.03 | 4.17 | 4.17 | 22.43 | 33.22 | 0.3373 | 3.33 | 6.55 | 1,974,311.00 | 6.28 | 3.69 | 6.55 | 3.84 | 55.49 | 56.79 | 18.60 | 12.19 | 2.02 | 5.10 | 0.4052 | 0.00 | -0.21 | 2.89 | 354.34 | -- | -1.84 | -- |
Perrigo Company PLC | 4.56bn | 700.00k | 3.54bn | 9.14k | 8,224.68 | 0.7558 | 10.04 | 0.7777 | 0.0032 | -0.0585 | 33.33 | 34.39 | 0.4219 | 2.54 | 5.78 | 498,457.30 | 0.0065 | -0.1148 | 0.0074 | -0.1315 | 35.65 | 35.28 | 0.0154 | -0.2985 | 1.08 | 1.26 | 0.4645 | -- | 4.58 | -0.3238 | 96.64 | -- | -5.95 | 7.52 |
Axsome Therapeutics Inc | 251.02m | -296.38m | 3.75bn | 545.00 | -- | 26.01 | -- | 14.93 | -6.38 | -6.38 | 5.41 | 3.03 | 0.537 | 2.11 | 3.43 | 460,592.70 | -63.40 | -64.55 | -85.88 | -82.23 | 90.12 | -- | -118.07 | -227.05 | 3.09 | -55.54 | 0.556 | -- | 440.80 | -- | -27.84 | -- | 77.86 | -- |
Avidity Biosciences Inc | 10.87m | -228.68m | 4.12bn | 253.00 | -- | 4.46 | -- | 378.88 | -2.95 | -2.95 | 0.1408 | 8.69 | 0.0139 | -- | -- | 42,964.43 | -29.22 | -31.61 | -31.71 | -34.45 | -- | -- | -2,103.78 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
Apellis Pharmaceuticals Inc | 524.07m | -417.27m | 4.25bn | 702.00 | -- | 15.91 | -- | 8.10 | -3.46 | -3.46 | 4.33 | 2.20 | 0.5788 | 0.5747 | 3.50 | 746,538.40 | -46.09 | -73.88 | -57.28 | -90.03 | 86.47 | -- | -79.62 | -326.49 | 3.02 | -39.71 | 0.6087 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
BridgeBio Pharma Inc | 218.60m | -538.26m | 4.66bn | 550.00 | -- | -- | -- | 21.32 | -3.23 | -3.23 | 1.29 | -5.61 | 0.2964 | -- | -- | 397,449.10 | -74.13 | -72.44 | -90.19 | -89.72 | 98.91 | 94.41 | -250.09 | -1,225.66 | -- | -11.48 | 2.53 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
Organon & Co | 6.35bn | 1.05bn | 5.17bn | 10.00k | 4.93 | 107.24 | 4.01 | 0.8152 | 4.08 | 4.08 | 24.71 | 0.1876 | 0.5603 | 2.18 | 4.24 | 634,700.00 | 9.24 | 16.53 | 11.79 | 20.97 | 59.04 | 65.12 | 16.50 | 26.79 | 1.15 | 2.36 | 0.9945 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 14.70m | 10.79% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 11.66m | 8.55% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 6.79m | 4.98% |
Dimensional Fund Advisors LPas of 31 Mar 2024 | 6.61m | 4.85% |
DePrince, Race & Zollo, Inc.as of 31 Mar 2024 | 3.49m | 2.56% |
Cooke & Bieler LPas of 31 Mar 2024 | 3.47m | 2.55% |
Davenport & Co. LLCas of 31 Mar 2024 | 3.45m | 2.53% |
Thompson, Siegel & Walmsley LLCas of 31 Mar 2024 | 3.44m | 2.53% |
Wolf Hill Capital Management LPas of 31 Mar 2024 | 3.06m | 2.24% |
Slate Path Capital LPas of 31 Mar 2024 | 2.85m | 2.09% |